Imunon Inc Net Assets
Imunon Inc net assets. Based on the latest financial reports, Imunon Inc (IMNN) has net assets worth $4.19 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.99 Million) and total liabilities ($10.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IMNN net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.19 Million |
| % of Total Assets | 27.95% |
| Annual Growth Rate | 0.15% |
| 5-Year Change | -87.34% |
| 10-Year Change | 5.0% |
| Growth Volatility | 239.47 |
Net Assets of Imunon Inc (1996–2025)
Net assets of Imunon Inc from 1996 to 2025. This chart illustrates how Imunon Inc's net assets have evolved over time, based on quarterly financial data. See IMNN net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Imunon Inc (1996–2025)
The table below shows the annual net assets of Imunon Inc from 1996 to 2025. For live market cap and overall valuation, see Imunon Inc (IMNN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.06 Million | +66.39% |
| 2024-12-31 | $4.24 Million | -68.30% |
| 2023-12-31 | $13.39 Million | -54.35% |
| 2022-12-31 | $29.33 Million | -47.44% |
| 2021-12-31 | $55.80 Million | +199.80% |
| 2020-12-31 | $18.61 Million | +27.83% |
| 2019-12-31 | $14.56 Million | -30.21% |
| 2018-12-31 | $20.86 Million | -21.88% |
| 2017-12-31 | $26.70 Million | +297.04% |
| 2016-12-31 | $6.73 Million | -67.01% |
| 2015-12-31 | $20.39 Million | -37.90% |
| 2014-12-31 | $32.83 Million | +4.13% |
| 2013-12-31 | $31.52 Million | +163.54% |
| 2012-12-31 | $11.96 Million | -54.33% |
| 2011-12-31 | $26.19 Million | +672.47% |
| 2010-12-31 | $-4.58 Million | -145.59% |
| 2009-12-31 | $10.04 Million | -49.13% |
| 2008-12-31 | $19.73 Million | -35.64% |
| 2007-12-31 | $30.65 Million | +1057.60% |
| 2006-12-31 | $-3.20 Million | -193.44% |
| 2005-12-31 | $3.43 Million | -71.38% |
| 2004-12-31 | $11.97 Million | -11.02% |
| 2003-12-31 | $13.45 Million | +787.11% |
| 2002-12-31 | $1.52 Million | -43.19% |
| 2001-12-31 | $2.67 Million | -69.41% |
| 2000-12-31 | $8.73 Million | +772.64% |
| 1999-12-31 | $1.00 Million | +154.02% |
| 1998-12-31 | $-1.85 Million | +24.77% |
| 1997-12-31 | $-2.46 Million | -136.42% |
| 1996-12-31 | $6.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Imunon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40908636700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Imunon Inc Net Assets Breakdown (December 2025)
Imunon Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $34.00K | 0.48% |
| Other Components | $428.33 Million | 6065.22% |
| Total Equity | $7.06 Million | 100.00% |
Imunon Inc Competitors by Market Cap
The table below lists competitors of Imunon Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TruCap Finance Limited
NSE:TRU
|
$5.05 Million |
|
Arrive AI Inc.
NASDAQ:ARAI
|
$5.06 Million |
|
Gaming Factory S.A.
WAR:GIF
|
$5.06 Million |
|
Aqua Metals Inc
NASDAQ:AQMS
|
$5.06 Million |
|
Labat Africa Ltd
JSE:LAB
|
$5.05 Million |
|
Schroder Japan Growth Fund
LSE:SJG
|
$5.05 Million |
|
Alchemy Resources Ltd
AU:ALY
|
$5.04 Million |
|
Goodbye Kansas Group AB (publ)
ST:GBK
|
$5.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imunon Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,244,298 to 7,062,000, a change of 2,817,702 (66.4%).
- Net loss of 14,495,000 reduced equity.
- Dividend payments of 10,277 reduced retained earnings.
- New share issuances of 13,628,070 increased equity.
- Other factors increased equity by 3,694,909.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.49 Million | -205.25% |
| Dividends Paid | $10.28K | -0.15% |
| Share Issuances | $13.63 Million | +192.98% |
| Other Changes | $3.69 Million | +52.32% |
| Total Change | $- | 66.39% |
Book Value vs Market Value Analysis
This analysis compares Imunon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $56710.10 | $0.90 | x |
| 1997-12-31 | $-18345.23 | $0.90 | x |
| 1998-12-31 | $-1275.81 | $0.90 | x |
| 1999-12-31 | $4609.36 | $0.90 | x |
| 2000-12-31 | $31077.03 | $0.90 | x |
| 2001-12-31 | $7816.16 | $0.90 | x |
| 2002-12-31 | $3677.32 | $0.90 | x |
| 2003-12-31 | $25039.54 | $0.90 | x |
| 2004-12-31 | $1068.92 | $0.90 | x |
| 2005-12-31 | $3936.85 | $0.90 | x |
| 2006-12-31 | $-3677.50 | $0.90 | x |
| 2007-12-31 | $35202.44 | $0.90 | x |
| 2008-12-31 | $23958.11 | $0.90 | x |
| 2009-12-31 | $11609.59 | $0.90 | x |
| 2010-12-31 | $-4557.30 | $0.90 | x |
| 2011-12-31 | $15435.22 | $0.90 | x |
| 2012-12-31 | $4238.79 | $0.90 | x |
| 2013-12-31 | $6377.47 | $0.90 | x |
| 2014-12-31 | $4868.06 | $0.90 | x |
| 2015-12-31 | $2560.05 | $0.90 | x |
| 2016-12-31 | $709.77 | $0.90 | x |
| 2017-12-31 | $685.03 | $0.90 | x |
| 2018-12-31 | $232.13 | $0.90 | x |
| 2019-12-31 | $130.47 | $0.90 | x |
| 2020-12-31 | $113.93 | $0.90 | x |
| 2021-12-31 | $2011.61 | $0.90 | x |
| 2022-12-31 | $53.55 | $0.90 | x |
| 2023-12-31 | $19.31 | $0.90 | x |
| 2024-12-31 | $4.81 | $0.90 | x |
| 2025-12-31 | $3.33 | $0.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imunon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -205.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.74x
- Recent ROE (-205.25%) is below the historical average (-131.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -28.62% | -2612.59% | 0.01x | 1.38x | $-2.61 Million |
| 1997 | 0.00% | -2516.88% | 0.15x | 0.00x | $-2.81 Million |
| 1998 | 0.00% | -2411.55% | 0.53x | 0.00x | $-4.02 Million |
| 1999 | -240.00% | -2400.00% | 0.06x | 1.60x | $-2.50 Million |
| 2000 | -52.11% | -132959.50% | 0.00x | 1.04x | $-5.42 Million |
| 2001 | -259.37% | 0.00% | 0.00x | 1.11x | $-7.19 Million |
| 2002 | -643.00% | 0.00% | 0.00x | 1.51x | $-9.90 Million |
| 2003 | -98.67% | 0.00% | 0.00x | 1.07x | $-14.62 Million |
| 2004 | -116.83% | -558.01% | 0.15x | 1.42x | $-15.18 Million |
| 2005 | -253.55% | -70.50% | 0.77x | 4.64x | $-9.03 Million |
| 2006 | 0.00% | -67.41% | 0.59x | 0.00x | $-7.26 Million |
| 2007 | 115.33% | 0.00% | 0.00x | 1.27x | $32.28 Million |
| 2008 | -59.75% | -471.45% | 0.11x | 1.20x | $-13.76 Million |
| 2009 | -151.39% | 0.00% | 0.00x | 1.48x | $-16.20 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.36 Million |
| 2011 | -88.66% | -1161.13% | 0.06x | 1.25x | $-25.84 Million |
| 2012 | -222.11% | 0.00% | 0.00x | 2.12x | $-27.76 Million |
| 2013 | -26.17% | -1650.27% | 0.01x | 1.45x | $-11.40 Million |
| 2014 | -77.67% | -5098.85% | 0.01x | 2.03x | $-28.78 Million |
| 2015 | -110.18% | -4492.22% | 0.01x | 2.41x | $-24.50 Million |
| 2016 | -327.90% | -4410.75% | 0.02x | 4.59x | $-22.73 Million |
| 2017 | -76.40% | -4080.44% | 0.01x | 1.78x | $-23.07 Million |
| 2018 | -56.96% | -2376.67% | 0.01x | 2.25x | $-13.97 Million |
| 2019 | -115.75% | -3370.31% | 0.01x | 2.63x | $-18.31 Million |
| 2020 | -115.43% | -4296.71% | 0.01x | 2.02x | $-23.34 Million |
| 2021 | -37.22% | -4153.85% | 0.01x | 1.33x | $-26.35 Million |
| 2022 | -122.40% | -7179.65% | 0.01x | 1.50x | $-38.83 Million |
| 2023 | -145.77% | -15611.98% | 0.01x | 1.64x | $-20.85 Million |
| 2024 | -438.71% | 0.00% | 0.00x | 2.29x | $-19.04 Million |
| 2025 | -205.25% | 0.00% | 0.00x | 1.74x | $-15.20 Million |
Industry Comparison
This section compares Imunon Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imunon Inc (IMNN) | $4.19 Million | -28.62% | 2.58x | $5.05 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more